---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-125464"
form_type: "8-K"
ticker: "IRIX"
cik: "0001006045"
company_name: "IRIDEX CORP"
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:29:02.557106+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Iridex Q3 revenue $11.6M (-10% YoY); net loss $1.9M; expects EBITDA breakeven in Q4

## Summary
- Total revenue $11.6M, down 10% YoY; retina revenue $6.5M (-18% YoY).
- Cyclo G6 glaucoma revenue $3.1M (+3% YoY) with 13,600 probes sold.
- Net loss $1.9M ($0.12/sh) vs $1.8M loss ($0.11/sh) in Q3'23; gross margin 37.3% vs 43.7%.
- Appointed Patrick Mercer as CEO (effective Oct 1, 2024); strategic review ongoing with multiple parties.
- New Medicare LCDs effective Nov 17, 2024 expected to boost glaucoma product adoption.

## SEC filing metadata
- accession: 0000950170-24-125464
- form_type: 8-K
- ticker: IRIX
- cik: 0001006045
- company_name: IRIDEX CORP
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006045/000095017024125464/0000950170-24-125464-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006045/000095017024125464/irix-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-125464
- JSON: https://secwatch.observer/filing/0000950170-24-125464.json
- Plain text: https://secwatch.observer/filing/0000950170-24-125464.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.